Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
End stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality.
Cardiovascular (CV) causes account for almost half of all-cause mortality. Increased left
ventricular mass (LVM) is a common finding in ESRD patients on dialysis and is an independent
predictor of survival. Yet, to date there is no established medical treatment to reduce CV
morbidity and mortality in ESRD patients on hemodialysis. Blockade of aldosterone action by
means of mineralocorticoid receptor antagonists (MRA) provides cardioprotection and improves
outcome in heart failure patients. Furthermore, the MRA spironolactone has recently been
shown to reduce LVM in patients with mild-to-moderate chronic kidney disease (CKD). The
investigators here hypothesize that spironolactone treatment is cardioprotective by reducing
LVM in ESRD patients on dialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Wuerzburg University Hospital
Collaborators:
Clinical Trial Center Wuerzburg (CTCW) German Federal Ministry of Education and Research